Showing results (1221-1230 of 1,523) with videos related to
Sort By:
Pageof 153
Journal of Digestive Diseases|October 31, 2020
Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosisHuan Tong, Can Gan, Bo Wei, et al.Investigational New Drugs|February 3, 2021
Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer modelsChao Shang, Yi-Long Zhu, Yi-Quan Li, et al.Journal for Immunotherapy of Cancer|July 2, 2020
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort studyXue Bai, De-Hua Wu, Si-Cong Ma, et al.Nature Communications|September 19, 2024
Decimeter-depth and polarization addressable color 3D meta-holographyDi Wang, Yi-Long Li, Xin-Ru Zheng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung AdenocarcinomaChao Zhang, Jianjun Zhang, Fang-Ping Xu, et al.International Journal of Biological Macromolecules|May 3, 2026
3D-printed cell-free bioactive scaffolds from methacrylated hyaluronic acid and silk fibroin incorporating platelet-rich plasma for adipose tissue regenerationWang Yang, Ruiquan Liu, Keyang Qian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung CancerCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.BMC Cancer|July 5, 2017
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)Qing Zhou, Yong Song, Xin Zhang, et al.The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.Therapeutic Advances in Medical Oncology|November 25, 2022
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)Shun Lu, Ying Cheng, Jianying Zhou, et al.Pageof 153